Abbott Laboratories (NYSE:ABT) Issues Q2 2025 Earnings Guidance

Abbott Laboratories (NYSE:ABT) issued an update on its second quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 1.230-1.270 for the period, compared to the consensus earnings per share estimate of 1.250. The company issued revenue guidance of -. Abbott Laboratories also updated its FY 2025 guidance to 5.050-5.250 EPS.

Analyst Ratings Changes

A number of analysts recently weighed in on ABT shares. Bank of America raised their target price on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 10th. Raymond James lifted their target price on Abbott Laboratories from $132.00 to $142.00 and gave the stock an “outperform” rating in a report on Thursday. Royal Bank of Canada upped their target price on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Thursday. Jefferies Financial Group boosted their price objective on Abbott Laboratories from $135.00 to $137.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Stifel Nicolaus boosted their price target on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a “buy” rating in a report on Thursday. Four investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $142.59.

Abbott Laboratories Price Performance

Shares of ABT opened at $131.00 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60. The firm has a market cap of $227.20 billion, a PE ratio of 17.12, a PEG ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The firm’s 50 day moving average price is $130.63 and its 200 day moving average price is $121.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.02. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.38 billion. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.80%. The ex-dividend date is Tuesday, April 15th. Abbott Laboratories’s payout ratio is 30.85%.

Insiders Place Their Bets

In related news, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the sale, the executive vice president now owns 71,928 shares in the company, valued at $9,625,404.96. This represents a 55.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total value of $3,054,573.50. Following the completion of the transaction, the executive vice president now directly owns 125,697 shares in the company, valued at approximately $16,152,064.50. This represents a 15.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 116,449 shares of company stock valued at $15,463,316 over the last 90 days. 0.46% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Abbott Laboratories

An institutional investor recently raised its position in Abbott Laboratories stock. Brighton Jones LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 51,719 shares of the healthcare product maker’s stock after purchasing an additional 4,755 shares during the quarter. Brighton Jones LLC’s holdings in Abbott Laboratories were worth $5,850,000 as of its most recent filing with the Securities and Exchange Commission. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.